Hospital readmissions following catheter ablation for atrial fibrillation with THERMOCOOL™ STSF/ THERMOCOOL™ ST catheter with CARTO™ 3 system versus TactiCath™ catheter with EnSite™ system
Aim: Radiofrequency (RF) catheter ablation (CA) is a mainstay treatment for atrial fibrillation (AF). RF catheters with contact force (CF) sensing technology and electroanatomical mapping systems enable real-time assessment of catheter tip-tissue interface CF, facilitating individualized and preci...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2024-12-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aim: Radiofrequency (RF) catheter ablation (CA) is a mainstay treatment for atrial fibrillation (AF). RF
catheters with contact force (CF) sensing technology and electroanatomical mapping systems enable
real-time assessment of catheter tip-tissue interface CF, facilitating individualized and precise CA. This
study examined inpatient hospital readmissions in patients with AF treated with THERMOCOOL™ ST/
THERMOCOOL™ STSF catheter with the CARTO™ 3 System versus TactiCath™ catheter with the EnSite™
System. Materials & methods: Patients undergoing CA for AF between 1 July 2019 to 30 November 2021
were identified from the Premier Healthcare Database and grouped based on use of THERMOCOOL
ST/STSF or TactiCath™. Study outcomes were all-cause, cardiovascular (CV)-, and AF-related inpatient
readmission at 91–365-day post-CA. Inverse probability of treatment weighting of propensity scores
balanced baseline patient, comorbidity and hospital characteristics. A weighted generalized estimating
equation (GEE) model examined differences in readmission outcomes. Results: A total of 15,518 patients
met inclusion criteria (THERMOCOOL ST/STSF, n = 13,001; TactiCath™, n = 2517). Patient characteristics
were generally well-balanced after weighting. Patients treated with THERMOCOOL ST/STSF + CARTO 3
had a 20% lower likelihood of all-cause inpatient readmissions (7.8 vs 9.3%, chi-square p = 0.041; odds
ratio [OR]: 0.80, 95% confidence interval [CI]: 0.66–0.96, GEE p = 0.019) and a 21% lower likelihood of
CV-related inpatient readmission (5.2 vs 6.2%, chi-square p = 0.133, OR: 0.79, 95% CI: 0.62–0.99, GEE
p = 0.043) in 91–365-days post-CA versus those treated with TactiCath™ + Ensite. No significant differences
were observed for AF-related readmissions. Conclusion: Patients undergoing CA for AF treated with
THERMOCOOL ST/STSF + CARTO 3 had a significantly lower risk of all-cause and CV-related inpatient
hospital readmission versus those treated with TactiCath™ + Ensite. |
|---|---|
| ISSN: | 2042-6313 |